AAA
AVTX icon

Affinity Asset Advisors’s Avalo Therapeutics AVTX Stock Holding History

Affinity Asset Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.6M Buy
2,900,000
+1,559,160
+116% +$24.6M 2.42% 11
2026
Q1 		$20M Buy
1,340,840
+289,786
+28% +$4.53M 1.03% 31
2025
Q4 		$19.1M Buy
1,051,054
+44,837
+4% +$757K 1.09% 30
2025
Q3 		$12.8M Buy
1,006,217
+398,345
+66% +$3.43M 1.11% 27
2025
Q2 		$3.03M Sell
607,872
-49,282
-7% -$230K 0.41% 49
2025
Q1 		$5.26M Buy
657,154
+106,389
+19% +$806K 0.5% 39
2024
Q4 		$4.09M Buy
550,765
+505,765
+1,124% +$5.41M 0.55% 42
2024
Q3 		$426K Hold
45,000
– – 0.06% 80
2024
Q2 		$561K Buy
45,000
+35,000
+350% +$454K 0.06% 87
2024
Q1 		$218K Buy
+10,000
New +$53.9K 0.03% 93

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Affinity Asset Advisors's AVTX Position: Q2 2026 in Review

Affinity Asset Advisors increased its Avalo Therapeutics (AVTX) stake by 116% in Q2 2026, buying an estimated $24.6M and bringing the position to 2,900,000 shares worth $53.6M. The position accounts for 2.42% of the portfolio, ranked #11.

Affinity Asset Advisors first reported a position in AVTX in Q1 2024 and has held it in 10 quarters since. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Affinity Asset Advisors held 2,900,000 shares of Avalo Therapeutics worth $53.6M as of Q2 2026.
  • Affinity Asset Advisors bought 1,559,160 Avalo Therapeutics shares in Q2 2026, an estimated $24.6M.
  • Avalo Therapeutics made up 2.42% of Affinity Asset Advisors's portfolio in Q2 2026, its #11 holding.
  • Affinity Asset Advisors first reported a position in Avalo Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.